Taysha Gene Therapies
Dallas
About Taysha Gene Therapies
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $743.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2025)
- Ticker: nasdaq:TSHA
- Website: tayshagtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/taysha-gene-therapies-119374 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.